{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:37Z","timestamp":1792166317419,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osimertinib resistance poses a major challenge in treating advanced EGFR-mutant lung adenocarcinoma (LUAD). Exosomes, key mediators of intercellular communication, may contribute to drug resistance, but their specific role in osimertinib resistance remains unclear. This study aimed to elucidate the function and mechanisms of hypoxia-induced exosomes (HExo) in promoting osimertinib resistance in LUAD, with the goal of identifying potential diagnostic biomarkers and therapeutic targets. Cell survival under osimertinib treatment was analyzed using CCK8 and colony formation assays, while exosomal LUCAT1 was identified via RNA-seq and validated by qRT-PCR. Biological roles of LUCAT1 were assessed through in vitro and in vivo experiments, including immunoblotting, RNA immunoprecipitation (RIP)-qPCR, xenograft tumor models, and organoid models. Results demonstrated that hypoxia-induced exosomal LUCAT1 reduced the sensitivity of recipient LUAD cells to osimertinib. Mechanistically, LUCAT1 promoted osimertinib resistance by preventing c-MET degradation and activating downstream AKT\/mTOR and ERK pathways. Targeting c-MET effectively restored osimertinib sensitivity in resistant cells. Moreover, higher levels of exosomal LUCAT1 were significantly associated with poor therapeutic responses to osimertinib in patients. In conclusion, hypoxia-induced exosomal LUCAT1 drives osimertinib resistance by stabilizing c-MET and activating its downstream pathways. Plasma exosomal LUCAT1 levels are closely linked to osimertinib resistance and may serve as an ideal liquid biopsy target for monitoring patient response.<\/jats:p>","DOI":"10.1038\/s41419-025-08100-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:14:19Z","timestamp":1761581659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hypoxia-induced exosomal LUCAT1 promotes osimertinib resistance in lung adenocarcinoma by stabilizing c-MET"],"prefix":"10.1038","volume":"16","author":[{"given":"Jianting","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiekun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-3989","authenticated-orcid":false,"given":"Bixing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4981","authenticated-orcid":false,"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-9233","authenticated-orcid":false,"given":"Yingchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8592-5800","authenticated-orcid":false,"given":"Zhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-8020","authenticated-orcid":false,"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"8100_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"8100_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12929-023-00898-3","volume":"30","author":"O Wattanathamsan","year":"2023","unstructured":"Wattanathamsan O, Chantaravisoot N, Wongkongkathep P, Kungsukool S, Chetprayoon P, Chanvorachote P, et al. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction. J Biomed Sci. 2023;30:4.","journal-title":"J Biomed Sci"},{"key":"8100_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"8100_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38.","journal-title":"Mol Cancer"},{"key":"8100_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/1753465815587820","volume":"9","author":"A Tartarone","year":"2015","unstructured":"Tartarone A, Lerose R. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. Ther Adv Respir Dis. 2015;9:242\u201350.","journal-title":"Ther Adv Respir Dis"},{"key":"8100_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol J Hematol Oncol. 2019;12:63.","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"8100_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"8100_CR8","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","volume":"31","author":"VA Papadimitrakopoulou","year":"2020","unstructured":"Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, et al. Osimertinib versus platinum\u2013pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31:1536\u201344.","journal-title":"Ann Oncol"},{"key":"8100_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023;14:1071.","journal-title":"Nat Commun"},{"key":"8100_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.201211138","volume":"200","author":"G Raposo","year":"2013","unstructured":"Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373\u201383.","journal-title":"J Cell Biol"},{"key":"8100_CR11","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.","journal-title":"Science"},{"key":"8100_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13046-021-01979-7","volume":"40","author":"F Yu","year":"2021","unstructured":"Yu F, Liang M, Huang Y, Wu W, Zheng B, Chen C. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK\/ERK signaling. J Exp Clin Cancer Res. 2021;40:179.","journal-title":"J Exp Clin Cancer Res"},{"key":"8100_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI81130","volume":"126","author":"N Kosaka","year":"2016","unstructured":"Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular vesicles in cancer. J Clin Invest. 2016;126:1163\u201372.","journal-title":"J Clin Invest"},{"key":"8100_CR14","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1038\/s41388-021-01960-w","volume":"40","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Zhao Y, Chen Q, Zhu S, Niu Y, Ye Z, et al. Hypoxic exosomal HIF-1\u03b1-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Oncogene. 2021;40:5505\u201317.","journal-title":"Oncogene"},{"key":"8100_CR15","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.7150\/thno.51797","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11:2860\u201375.","journal-title":"Theranostics"},{"key":"8100_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41576-018-0017-y","volume":"19","author":"B Uszczynska-Ratajczak","year":"2018","unstructured":"Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guig\u00f3 R, Johnson R. Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet. 2018;19:535\u201348.","journal-title":"Nat Rev Genet"},{"key":"8100_CR17","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1101\/gr.132159.111","volume":"22","author":"T Derrien","year":"2012","unstructured":"Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775\u201389.","journal-title":"Genome Res"},{"key":"8100_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452\u201363.","journal-title":"Cancer Cell"},{"key":"8100_CR19","doi-asserted-by":"publisher","first-page":"20170074","DOI":"10.1098\/rstb.2017.0074","volume":"373","author":"DJ Hanly","year":"2018","unstructured":"Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? Philos Trans R Soc B Biol Sci. 2018;373:20170074 5.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"8100_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.bbrc.2017.11.121","volume":"495","author":"Z Han","year":"2018","unstructured":"Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c\/ABCB1 axis. Biochem Biophys Res Commun. 2018;495:947\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"8100_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1122-z","volume":"19","author":"L Huan","year":"2020","unstructured":"Huan L, Guo T, Wu Y, Xu L, Huang S, Xu Y, et al. Hypoxia induced LUCAT1\/PTBP1 axis modulates cancer cell viability and chemotherapy response. Mol Cancer. 2020;19:11.","journal-title":"Mol Cancer"},{"key":"8100_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0176-5","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang G, Tan X, Ke K, Zhao B, Cheng N, et al. MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53. Oncogenesis. 2019;8:67.","journal-title":"Oncogenesis"},{"key":"8100_CR23","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1111\/1759-7714.15093","volume":"14","author":"J Du","year":"2023","unstructured":"Du J, Zhang S, Zhang X, Yang Z, Xue S, Xu G, et al. miR -1301-3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression. Thorac Cancer. 2023;14:3032\u201341.","journal-title":"Thorac Cancer"},{"key":"8100_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-020-00223-6","volume":"5","author":"B Zhao","year":"2020","unstructured":"Zhao B, Ke K, Wang Y, Wang F, Shi Y, Zheng X, et al. HIF-1\u03b1 and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC metastasis. Signal Transduct Target Ther. 2020;5:118.","journal-title":"Signal Transduct Target Ther"},{"key":"8100_CR25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2012.171","volume":"9","author":"MR Horsman","year":"2012","unstructured":"Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9:674\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"8100_CR26","doi-asserted-by":"publisher","first-page":"e159839","DOI":"10.1172\/JCI159839","volume":"132","author":"EE Wicks","year":"2022","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132:e159839.","journal-title":"J Clin Invest"},{"key":"8100_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38:81.","journal-title":"J Exp Clin Cancer Res"},{"key":"8100_CR28","doi-asserted-by":"publisher","first-page":"671082","DOI":"10.3389\/fonc.2021.671082","volume":"11","author":"Y Chi","year":"2021","unstructured":"Chi Y, Xin H, Liu Z. Exosomal lncRNA UCA1 Derived From Pancreatic Stellate Cells Promotes Gemcitabine Resistance In Pancreatic Cancer via the SOCS3\/EZH2 Axis. Front Oncol. 2021;11:671082.","journal-title":"Front Oncol"},{"key":"8100_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fmolb.2020.00033","volume":"7","author":"C Jensen","year":"2020","unstructured":"Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture?. Front Mol Biosci. 2020;7:33.","journal-title":"Front Mol Biosci"},{"key":"8100_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1126\/science.1142946","volume":"318","author":"JM Stommel","year":"2007","unstructured":"Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287\u201390.","journal-title":"Science"},{"key":"8100_CR31","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u20139.","journal-title":"Ann Oncol"},{"key":"8100_CR32","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.phrs.2023.106668","volume":"188","author":"T Lei","year":"2023","unstructured":"Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C, et al. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis. Pharm Res. 2023;188:106668.","journal-title":"Pharm Res"},{"key":"8100_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2020.05.009","volume":"486","author":"C Chen","year":"2020","unstructured":"Chen C, Liu WR, Zhang B, Zhang LM, Li CG, Liu C, et al. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. Cancer Lett. 2020;486:58\u201370.","journal-title":"Cancer Lett"},{"key":"8100_CR34","doi-asserted-by":"publisher","first-page":"BSR20190489","DOI":"10.1042\/BSR20190489","volume":"39","author":"E Mou","year":"2019","unstructured":"Mou E, Wang H. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702. Biosci Rep. 2019;39:BSR20190489.","journal-title":"Biosci Rep"},{"key":"8100_CR35","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/neuonc\/noae036","volume":"26","author":"H Huang","year":"2024","unstructured":"Huang H, Shah H, Hao J, Lin J, Prayson RA, Xie L, et al. Long non-coding RNA lung cancer-associated transcript-1 promotes glioblastoma progression by enhancing Hypoxia-inducible factor 1 alpha activity. Neuro-Oncol. 2024;26:1388\u2013401.","journal-title":"Neuro-Oncol"},{"key":"8100_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","volume":"14","author":"S Liti\u00e8re","year":"2017","unstructured":"Liti\u00e8re S, Collette S, de Vries EGE, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017;14:187\u201392.","journal-title":"Nat Rev Clin Oncol"},{"key":"8100_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jhep.2015.02.009","volume":"63","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015;63:114\u201321.","journal-title":"J Hepatol"},{"key":"8100_CR38","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.7150\/thno.17895","volume":"7","author":"YJ Lin","year":"2017","unstructured":"Lin YJ, Shyu WC, Chang CW, Wang CC, Wu CP, Lee HT, et al. Tumor hypoxia regulates forkhead box C1 to promote lung cancer progression. Theranostics. 2017;7:1177\u201391.","journal-title":"Theranostics"},{"key":"8100_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ccell.2014.09.005","volume":"26","author":"SA Melo","year":"2014","unstructured":"Melo SA, Sugimoto H, O\u2019Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26:707\u201321.","journal-title":"Cancer Cell"},{"key":"8100_CR40","doi-asserted-by":"crossref","unstructured":"Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins. Oncogene. 2018;37:3806\u201321.","DOI":"10.1038\/s41388-018-0189-0"},{"key":"8100_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.833579","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Xie Y, Wang J, Zhang Y, Liu S, Zhan Y, et al. Characterization of a novel LUCAT1\/miR-4316\/VEGF-a axis in metastasis and glycolysis of lung adenocarcinoma. Front Cell Dev Biol. 2022;10:833579.","journal-title":"Front Cell Dev Biol"},{"key":"8100_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3892\/ijo.2024.5652","volume":"64","author":"F Tai","year":"2024","unstructured":"Tai F, Zhai R, Ding K, Zhang Y, Yang H, Li H, et al. Long non\u2011coding RNA lung cancer\u2011associated transcript 1 regulates ferroptosis via microRNA\u201134a\u20115p\u2011mediated GTP cyclohydrolase 1 downregulation in lung cancer cells. Int J Oncol. 2024;64:64.","journal-title":"Int J Oncol"},{"key":"8100_CR43","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/hum.2018.146","volume":"30","author":"X Wang","year":"2019","unstructured":"Wang X, Guo S, Zhao R, Liu Y, Yang G. STAT3-activated long non-coding RNA lung cancer associated transcript 1 drives cell proliferation, migration, and invasion in hepatoblastoma through regulation of the miR-301b\/STAT3 axis. Hum Gene Ther. 2019;30:702\u201313.","journal-title":"Hum Gene Ther"},{"key":"8100_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","volume":"29","author":"L Qu","year":"2016","unstructured":"Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-transmitted lncARSR Promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653\u201368.","journal-title":"Cancer Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08100-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08100-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:05:51Z","timestamp":1761908751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08100-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8100"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08100-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol for animal experiments was approved by Mengchao Hepatobiliary Hospital Medical Ethics Committee of Fujian Medical University. All animal care procedures and experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) guidelines. For human samples, all the subjects provided their written informed consent, and the study protocol was approved by the Ethics Committee of Fujian Medical University Union Hospital (No. 2024KY140).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"763"}}